PROTAC Technology: Opportunities and Challenges

Hongying Gao; Xiuyun Sun; Yu Rao

doi:10.1021/acsmedchemlett.9b00597

PROTAC Technology: Opportunities and Challenges

ACS Med Chem Lett. 2020 Mar 12;11(3):237-240. doi: 10.1021/acsmedchemlett.9b00597.

Authors

Hongying Gao^{1

2}, Xiuyun Sun^{1

2}, Yu Rao¹

Affiliations

¹ MOE Key Laboratory of Protein Sciences, School of Pharmaceutical Sciences, MOE Key Laboratory of Bioorganic Phosphorus Chemistry & Chemical Biology, Tsinghua University, Beijing 100084, P.R. China.
² Tsinghua University-Peking University Joint Center for Life Sciences, Beijing 100084, P.R. China.

Abstract

PROTACs-induced targeted protein degradation has emerged as a novel therapeutic strategy in drug development and attracted the favor of academic institutions, large pharmaceutical enterprises (e.g., AstraZeneca, Bayer, Novartis, Amgen, Pfizer, GlaxoSmithKline, Merck, and Boehringer Ingelheim, etc.), and biotechnology companies. PROTACs opened a new chapter for novel drug development. However, any new technology will face many new problems and challenges. Perspectives on the potential opportunities and challenges of PROTACs will contribute to the research and development of new protein degradation drugs and degrader tools.